Pfizer To Present New Research From Fifteen Compounds

PfizerPfizer Inc. will present more than 30 abstracts, including data from investigational compounds, axitinib,(1) crizotinib,(2) and bosutinib,(3) as well as data evaluating Sutent® (sunitinib malate), across multiple tumor types,(4,5) at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7. The Company will also share analyses from early stage compounds focused on the science behind tumor growth.(6,7,8)

"The research we are presenting at ASCO represents Pfizer's continued commitment to finding novel treatment solutions and improving the lives of patients with cancer," said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. "We are excited to present data demonstrating the efficacy and tolerability of several of our late-stage compounds, while also highlighting early phase clinical research exploring key mechanisms and promising pathways which may help inspire new potential therapeutic approaches for many difficult to treat cancers."

Axitinib
Pfizer is presenting results from the Phase 3 AXIS 1032 trial, comparing axitinib to sorafenib in patients with previously-treated advanced renal cell carcinoma (RCC). These are the first pivotal head-to-head data comparing active, targeted therapies in advanced RCC (Oral presentation, Abstract #4503, June 6).(1) In addition, two other axitinib RCC abstracts will be presented.

  • Patient-reported outcomes (PRO) from the AXIS 1032 trial (Oral presentation, Abstract #4504, June 6) (9)
  • Five-year overall survival data from a Phase 2 trial of axitinib as a second-line treatment for patients with metastatic RCC (Poster discussion, Abstract #4547, June 7) (10)

Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, (1) receptors that can influence tumor growth, vascular angiogenesis and progression of cancer (the spread of tumors).

Crizotinib
At ASCO, Pfizer will publicly present for the first time data from an early stage study demonstrating the impact of crizotinib, an oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, compared to historical controls, on overall survival in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) (Oral presentation, Abstract #7507, June 5). (2)

  • Updated progression-free survival (PFS) from a Part 2 expansion cohort of a Phase 1 study in patients with ALK-positive advanced NSCLC (Clinical Science Symposium, Abstract #2501, June 3) (11)
  • Initial Phase 2 results of crizotinib in advanced ALK-positive NSCLC (Poster discussion, Abstract #7514, June 6) (12)

Bosutinib
Pfizer continues to investigate the potential of targeting specific pathways in hematologic malignancies, and will provide an update on clinical trials of bosutinib as a single agent in both newly diagnosed3 and previously treated patients with Philadelphia chromosome positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML). (13)

  • 18-month follow up data from the Bosutinib Efficacy and safety in chronic myeloid LeukemiA [BELA] Phase 3 study evaluating bosutinib as a first-line treatment in patients with CP CML (Poster discussion, Abstract #6509, June 3) (3)
  • Bosutinib as third-line therapy for CP CML patients following failure of or intolerance to imatinib and dasatinib or nilotinib (Study 200) (Abstract #6535, June 6) (15)
  • Health-related quality of life in newly diagnosed (Abstract #6612, June 6)14 and imatinib-resistant or imatinib intolerant CP CML patients (Abstract #6620, June 6) (15)

Bosutinib is an investigational oral dual Src and Abl kinase inhibitor with minimal inhibitory activity against c-kit and PDGFR. (16) It is believed that by dual inhibition of the Src and Abl tyrosine kinases, bosutinib may inhibit signaling in CML cells that allows the cells to grow, survive and reproduce. (17)

Sutent
Since its approval in 2006, Sutent has changed the treatment landscape for advanced RCC and imatinib-resistant or -intolerant gastrointestinal stromal tumors (GIST) and remains a standard of care in these indications.

In November 2010, Sutent was approved in Europe for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults. Experience with Sutent as first-line treatment is limited. Sutent is currently under review by the U.S. FDA for the treatment of unresectable pancreatic NET.

At ASCO, Pfizer will present new analyses from trials evaluating Sutent in patients with advanced unresectable pancreatic NET4 and in patients with metastatic RCC.(5)

  • Updated overall survival and progression-free survival data by blinded independent central review (BICR) of sunitinib versus placebo for patients with advanced unresectable pancreatic NET (Poster discussion, Abstract #4008, June 6) (4)
  • Circulating protein biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic RCC (Poster discussion, Abstract #10525, June 4) (18)
  • A pooled analysis of the efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma (mRCC) (Abstract #4604, June 5) (5)

Additionally at ASCO, results from Phase 3 studies of sunitinib in metastatic castration-resistant prostate cancer (mCRPC) (19) and advanced hepatocellular carcinoma (HCC) (20) will be presented.

Pfizer announced last year that these studies did not meet their primary endpoints.

  • Phase 3 trial of sunitinib with prednisone versus prednisone alone in mCRPC (Oral presentation, Abstract #4515, June 6) (19)
  • Phase 3 trial of sunitinib versus sorafenib in advanced HCC (Oral presentation, Abstract #4000, June 7) (20)

Early Development Compounds
Pfizer will present data from its early stage pipeline evaluating multiple compounds targeting innovative pathways.

  • Phase 1 study of PF-04554878, a focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors (Clinical Science Symposium, Abstract #3002, June 5) (6)
  • Phase 1 study of PF-03446962, a fully human monoclonal antibody (mAb) against activin receptor-like kinase 1 (ALK-1), a TGFβ receptor involved in tumor angiogenesis (Oral presentation, Abstract #3009, June 5) (7)
  • Randomized Phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor positive, HER2-negative advanced breast cancer (Abstract #TPS100, June 6) (8)

Data on the following compounds and investigational agents will also be presented: Torisel (temsirolimus) (mantle cell lymphoma), (21) neratinib (breast cancer), (22) PF-00299804 (head and neck cancer), (23) figitumumab (colorectal cancer), (24) tremelimumab (pancreatic cancer), (25) gamma secretase inhibitor – PF-03084014 (solid tumors), (26) PARP (poly ADP ribose polymerase) inhibitor – PF-01367338 (peripheral blood lymphocytes), (27) dual angiopoietin-2 (Ang2) and VEGF inhibitor – CVX-241 (solid tumors). (28)

About Sutent(®) (sunitinib malate)
Sutent is an oral multi-kinase inhibitor that works by blocking multiple molecular targets implicated in the growth, proliferation and spread of cancer. Two important Sutent targets, vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) are expressed by many types of solid tumors and are thought to play a crucial role in angiogenesis, the process by which tumors acquire blood vessels, oxygen and nutrients needed for growth. Sutent also inhibits other targets important to tumor growth, including KIT, FLT3 and RET.

About Torisel® (temsirolimus)
Torisel is the only intravenous mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of advanced renal cell carcinoma (RCC).

Based on preclinical studies, Torisel inhibits the activity of mTOR, an intracellular protein implicated in multiple growth-related cellular functions including proliferation, growth and survival. The inhibition of mTOR also reduces levels of certain growth factors, such as vascular endothelial growth factor (VEGF), which are overexpressed in solid tumors like kidney cancer and are thought to play a crucial role in angiogenesis, the process by which tumors acquire blood vessels, nutrients and oxygen needed for growth.

About Pfizer Oncology
Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. Pfizer Oncology has biologics and small molecules in clinical development and more than 100 clinical trials underway. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug for each patient at the right time.

1. ASCO Accepted Abstract #4503. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. Oral Presentation, Monday, June 6, 2011: 8:00-8:15 AM. B. Rini – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
2. ASCO Accepted Abstract #7507. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. Oral Presentation, Sunday, June 5, 2011: 10:45-11:00 AM. A. Shaw – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
3. ASCO Accepted Abstract #6509. Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up. Poster Discussion Session, Friday, June 3, 2011: 2:00-6:00 PM. C. Gambacorti–Passerini – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
4. ASCO Accepted Abstract #4008. Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). Poster Discussion Session, Monday, June 6, 2011: 2:00-6:00 PM. E. Raymond – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
5. ASCO Accepted Abstract #4604. A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). Poster Session, Sunday, June 5, 2011: 8:00 AM – 12:00 PM. T. Hutson – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
6. ASCO Accepted Abstract #3002. Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors. Clinical Science Symposium, Sunday, June 5, 2011: 5:30-5:45 PM. S. Jones – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
7. ASCO Accepted Abstract #3009. Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFß receptor involved in tumor angiogenesis. Oral Presentation, Sunday, June 5, 2011: 11:45 AM – 12:00 PM. L. Goff – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
8. ASCO Accepted Abstract #TPS100. A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Trials in Progress Poster Session, Monday, June 6, 2011: 8:00 AM – 12:00 PM. R. Finn – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
9. ASCO Accepted Abstract #4504. Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). Oral Presentation, Monday, June 6, 2011: 8:15-8:30AM. D. Cella – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
10. ASCO Accepted Abstract #4547. Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial. Poster Discussion Session, Tuesday, June 7, 2011: 8:00 AM – 12:00 PM. R. Motzer – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
11. ASCO Accepted Abstract #2501. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). Clinical Science Symposium, Friday, June 3, 2011: 3:30-3:45PM. R. Camidge – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
12. ASCO Accepted Abstract #7514. Initial phase 2 results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. Poster Discussion Session, Monday, June 6, 2011: 2:00 – 6:00 PM. L. Crinò – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
13. ASCO Accepted Abstract #6535. Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL). Poster Session, Monday, June 6, 2011: 1:00-6:00 PM. T. Brummendorf – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
14. ASCO Accepted Abstract #6612. Health-related quality of life (HRQoL) in newly diagnosed patients (pts) with chronic phase chronic myelogenous leukemia (CP CML) treated with bosutinib (BOS) or imatinib (IM). Poster Session, Monday, June 6, 2011: 1:00-5:00 PM. J. Lipton – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
15. ASCO Accepted Abstract #6620. Health-related quality of life (HRQoL) of bosutinib (SKI-606) in imatinib-resistant (IM-R) or imatinib-intolerant (IM-I) chronic phase chronic myeloid leukemia (CP CML). Poster Session, Monday, June 6, 2011: 1:00-5:00 PM. P. Trask – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
16. Gambacorti-Passerini C et al. Bosutinib (SKI-606) Demonstrates Clinical Activity and is Well Tolerated in Patients with AP and BP CML and Ph+ ALL. Poster Presented at the American Society of Hematology Meeting, December 6-9, 2008, San Francisco, CA. Wyeth.
17. Konig H et al. Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells. Cancer Research. 2008; 68: 9624-9633.
18. ASCO Accepted Abstract # 10525. Circulating protein biomarkers of sunitinib (SU) and interferon-alpha (IFN-alpha) efficacy in treatment (Tx)-naïve patients (pts) with metastatic renal cell carcinoma (mRCC). Poster Discussion, Saturday, June 4, 2011: 5:00 – 6:00 PM. S. Harmon – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
19. ASCO Accepted Abstract #4515. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). Oral Presentation, Monday June 6, 2011: 1:00 – 1:15 PM. M.D. Michaelson – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
20. ASCO Accepted Abstract #4000. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). Oral Presentation, Tuesday, June 7, 2011: 9:30-9:45 AM. A. Cheng – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
21. ASCO Accepted Abstract #TPS222. Randomized phase IV trial comparing efficacy and tolerability of temsirolimus with and without an elevated starting dose in patients with relapsed, refractory mantle cell lymphoma. Trials in Progress Poster Session, Monday, June 6, 2011: 8:00 AM -12:00 PM. A. Blair – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
22. ASCO Accepted Abstract #TPS137. A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC). Trials in Progress Poster Session, Monday, June 6, 2011: 8:00 AM -12:00 PM. P. Goss – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
23. ASCO Accepted Abstract #5561. Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Poster Session, Saturday, June 4, 2011: 2:00 PM – 6:00 PM. L. Siu – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
24. ASCO Accepted Abstract #3525. Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC). Poster Discussion Session, Monday, June 6, 2011: 8:00 AM – 12:00 PM. C. Becerra – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
25. ASCO Accepted Abstract #4081. Final toxicity results of a phase I dose-escalation trial of tremelimumab (CP-675206) in combination with gemcitabine in chemotherapy-naive patients (pts) with metastatic pancreatic cancer. Poster Session, Saturday, June 4, 2011: 8:00 AM – 12:00 PM. M. Aglietta – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
26. ASCO Accepted Abstract #3100. A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors. Poster Session, Monday, June 6, 2011: 8:00 AM – 12:00 PM. W. Messersmith – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
27. ASCO Accepted Abstract #3054. Poly (ADP ribose) polymerase (PARP) inhibition in peripheral blood lymphocytes (PBLs): Does it reflect PARP inhibition in tumor? Poster Session, Monday, June 6, 2011: 8:00 AM -12:00 PM. D. Shalinsky – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.
28. ASCO Accepted Abstract #3055. First-in-human dose-escalation safety and PD trial of a novel humanized monoclonal CovX body inhibitor of angiopoietin 2 and vascular endothelial growth factor. Poster Session, Monday, June 6, 2011: 8:00 AM – 12:00 PM. D. Mendelson – Presenter. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. June 3-7, 2011.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

SMi Group announces the 9th Annual RNA Therapeutic…

21 - 22 February 2018, London, UK. As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]